Limits...
Anti-C1q antibodies as a follow-up marker in SLE patients.

Bock M, Heijnen I, Trendelenburg M - PLoS ONE (2015)

Bottom Line: Anti-C1q levels correlated with global disease activity scores.In subgroup analyses, patients without renal involvement did not show a significant correlation between anti-C1q levels and disease activity.In contrast, in patients with renal involvement, anti-C1q levels correlated well with global disease activity.

View Article: PubMed Central - PubMed

Affiliation: Division of Internal Medicine, University Hospital Basel, Basel, Switzerland.

ABSTRACT
In cross-sectional studies autoantibodies against complement C1q (anti-C1q) were found to be highly associated with active lupus nephritis. The aim of this retrospective study was to determine the value of anti-C1q as follow-up marker of disease activity and renal involvement in patients with systemic lupus erythematosus (SLE). Fifty-two patients with SLE and a minimum of three anti-C1q measurements during follow-up were analyzed. Anti-C1q levels correlated with global disease activity scores. In subgroup analyses, patients without renal involvement did not show a significant correlation between anti-C1q levels and disease activity. In contrast, in patients with renal involvement, anti-C1q levels correlated well with global disease activity. In addition, a positive correlation with the urine protein-to-creatinine ratio and anti-dsDNA antibody levels as well as a negative correlation with complement levels was observed. Anti-C1q antibodies were found to strongly correlate with parameters of SLE disease activity during follow-up, in particular with regard to renal involvement.

No MeSH data available.


Related in: MedlinePlus

Correlation between anti-C1q and urine protein-to-creatinine ratio, anti-dsDNA antibodies and complement C3, C4, and CH50 for all patients, patients without renal involvement and patients with renal involvement.1) = all patients, 2) = only patients without renal involvement, 3) = only patients with renal involvement (A) Correlation between anti-C1q and urine protein-to-creatinine ratio: (A1): R = 0.41, p<0.0001; (A2): R = 0.32, p = 0.01; p<0.0001 (A3): R = 0.28, p<0.0001; (B) Correlation between anti-C1q and anti-dsDNA measured with Farr assay: (B1): R = 0.59, p<0.0001; (B2): R = 0.4, p = 0.01; (B3): R = 0.6, p<0.0001; (C) Correlation between anti-C1q and anti-dsDNA measured with FEIA: (C1): R = 0.42, p<0.0001; (C2): R = 0.37, p = 0.002; (C3): R = 0.47, p<0.0001; (D) Correlation between anti-C1q and complement C3: (D1): R = -0.36, p<0.0001; (D2): R = -0.33, p = 0.0003; (D3): R = -0.3, p<0.0001; (E) Correlation between anti-C1q and C4: (E1): R = -0.24, p<0.0001; (E2): R = -0.35, p = 0.0001; (E3): R = 0.16; p = 0.006; (F) Correlation between anti-C1q and CH50: (F1): R = -0.26, p<0.0001; (F2): R = -0.42, p = 0.002; (F3): R = -0.3, p<0.0001.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4400137&req=5

pone.0123572.g004: Correlation between anti-C1q and urine protein-to-creatinine ratio, anti-dsDNA antibodies and complement C3, C4, and CH50 for all patients, patients without renal involvement and patients with renal involvement.1) = all patients, 2) = only patients without renal involvement, 3) = only patients with renal involvement (A) Correlation between anti-C1q and urine protein-to-creatinine ratio: (A1): R = 0.41, p<0.0001; (A2): R = 0.32, p = 0.01; p<0.0001 (A3): R = 0.28, p<0.0001; (B) Correlation between anti-C1q and anti-dsDNA measured with Farr assay: (B1): R = 0.59, p<0.0001; (B2): R = 0.4, p = 0.01; (B3): R = 0.6, p<0.0001; (C) Correlation between anti-C1q and anti-dsDNA measured with FEIA: (C1): R = 0.42, p<0.0001; (C2): R = 0.37, p = 0.002; (C3): R = 0.47, p<0.0001; (D) Correlation between anti-C1q and complement C3: (D1): R = -0.36, p<0.0001; (D2): R = -0.33, p = 0.0003; (D3): R = -0.3, p<0.0001; (E) Correlation between anti-C1q and C4: (E1): R = -0.24, p<0.0001; (E2): R = -0.35, p = 0.0001; (E3): R = 0.16; p = 0.006; (F) Correlation between anti-C1q and CH50: (F1): R = -0.26, p<0.0001; (F2): R = -0.42, p = 0.002; (F3): R = -0.3, p<0.0001.

Mentions: The overall associations between anti-C1q levels and the laboratory parameters CH50, C3, C4, anti-dsDNA, and urine protein-to-creatinine ratio for all data points of the 52 included SLE patients are demonstrated in Fig 4.


Anti-C1q antibodies as a follow-up marker in SLE patients.

Bock M, Heijnen I, Trendelenburg M - PLoS ONE (2015)

Correlation between anti-C1q and urine protein-to-creatinine ratio, anti-dsDNA antibodies and complement C3, C4, and CH50 for all patients, patients without renal involvement and patients with renal involvement.1) = all patients, 2) = only patients without renal involvement, 3) = only patients with renal involvement (A) Correlation between anti-C1q and urine protein-to-creatinine ratio: (A1): R = 0.41, p<0.0001; (A2): R = 0.32, p = 0.01; p<0.0001 (A3): R = 0.28, p<0.0001; (B) Correlation between anti-C1q and anti-dsDNA measured with Farr assay: (B1): R = 0.59, p<0.0001; (B2): R = 0.4, p = 0.01; (B3): R = 0.6, p<0.0001; (C) Correlation between anti-C1q and anti-dsDNA measured with FEIA: (C1): R = 0.42, p<0.0001; (C2): R = 0.37, p = 0.002; (C3): R = 0.47, p<0.0001; (D) Correlation between anti-C1q and complement C3: (D1): R = -0.36, p<0.0001; (D2): R = -0.33, p = 0.0003; (D3): R = -0.3, p<0.0001; (E) Correlation between anti-C1q and C4: (E1): R = -0.24, p<0.0001; (E2): R = -0.35, p = 0.0001; (E3): R = 0.16; p = 0.006; (F) Correlation between anti-C1q and CH50: (F1): R = -0.26, p<0.0001; (F2): R = -0.42, p = 0.002; (F3): R = -0.3, p<0.0001.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4400137&req=5

pone.0123572.g004: Correlation between anti-C1q and urine protein-to-creatinine ratio, anti-dsDNA antibodies and complement C3, C4, and CH50 for all patients, patients without renal involvement and patients with renal involvement.1) = all patients, 2) = only patients without renal involvement, 3) = only patients with renal involvement (A) Correlation between anti-C1q and urine protein-to-creatinine ratio: (A1): R = 0.41, p<0.0001; (A2): R = 0.32, p = 0.01; p<0.0001 (A3): R = 0.28, p<0.0001; (B) Correlation between anti-C1q and anti-dsDNA measured with Farr assay: (B1): R = 0.59, p<0.0001; (B2): R = 0.4, p = 0.01; (B3): R = 0.6, p<0.0001; (C) Correlation between anti-C1q and anti-dsDNA measured with FEIA: (C1): R = 0.42, p<0.0001; (C2): R = 0.37, p = 0.002; (C3): R = 0.47, p<0.0001; (D) Correlation between anti-C1q and complement C3: (D1): R = -0.36, p<0.0001; (D2): R = -0.33, p = 0.0003; (D3): R = -0.3, p<0.0001; (E) Correlation between anti-C1q and C4: (E1): R = -0.24, p<0.0001; (E2): R = -0.35, p = 0.0001; (E3): R = 0.16; p = 0.006; (F) Correlation between anti-C1q and CH50: (F1): R = -0.26, p<0.0001; (F2): R = -0.42, p = 0.002; (F3): R = -0.3, p<0.0001.
Mentions: The overall associations between anti-C1q levels and the laboratory parameters CH50, C3, C4, anti-dsDNA, and urine protein-to-creatinine ratio for all data points of the 52 included SLE patients are demonstrated in Fig 4.

Bottom Line: Anti-C1q levels correlated with global disease activity scores.In subgroup analyses, patients without renal involvement did not show a significant correlation between anti-C1q levels and disease activity.In contrast, in patients with renal involvement, anti-C1q levels correlated well with global disease activity.

View Article: PubMed Central - PubMed

Affiliation: Division of Internal Medicine, University Hospital Basel, Basel, Switzerland.

ABSTRACT
In cross-sectional studies autoantibodies against complement C1q (anti-C1q) were found to be highly associated with active lupus nephritis. The aim of this retrospective study was to determine the value of anti-C1q as follow-up marker of disease activity and renal involvement in patients with systemic lupus erythematosus (SLE). Fifty-two patients with SLE and a minimum of three anti-C1q measurements during follow-up were analyzed. Anti-C1q levels correlated with global disease activity scores. In subgroup analyses, patients without renal involvement did not show a significant correlation between anti-C1q levels and disease activity. In contrast, in patients with renal involvement, anti-C1q levels correlated well with global disease activity. In addition, a positive correlation with the urine protein-to-creatinine ratio and anti-dsDNA antibody levels as well as a negative correlation with complement levels was observed. Anti-C1q antibodies were found to strongly correlate with parameters of SLE disease activity during follow-up, in particular with regard to renal involvement.

No MeSH data available.


Related in: MedlinePlus